Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma

British Journal of Cancer

Volumn 83, Issue 2, 2000, Pages 146-152

  Ford, H E R ^a,b   Cunningham, D ^a   Ross, P J ^a   Rao, S ^a   Aherne, G W ^b   Benepal, T S ^a   Price, T ^a   Massey, A ^a   Vernillet, L ^c   Gruia, G ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c SANOFI   (France)

Author keywords

Drug combination; Irinotecan; Pharmacokinetics; Phase I; Raltitrexed

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG SAFETY; ESOPHAGUS CARCINOMA; FEMALE; FEVER; GASTROINTESTINAL CARCINOMA; HUMAN; LETHARGY; LIVER DYSFUNCTION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA;

EID: 0034086719     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1192     Document Type: Article

References (25)

1. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P and Gandia D (1994) Irinotecan (CPT-11) high dose escalation using intensive high-dose loperamide to control diarrhoea. J Natl Cancer Inst 86: 446-449
2. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A and Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221
3. Aherne GW, Ward E, Lawrence N, Dobinson D, Clarke SJ, Musgrove H, Sutcliffe F, Stephens T and Jackman AL (1998) Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamable quinazoline thymidylate synthase inhibitor in preclinical models. Br J Cancer 77: 221-226
4. Armand JP (1996) CPT-11: clinical experience in phase 1 studies. Semin Oncol 23 (suppl. 3): 27-33
5. Aschele C, Baldo C, Sobrero A, Debernardis D, Bornmann WG and Bertino JR (1998) Schedule dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clinical Cancer Research 4: 1323-1330
6. Beale P, Judson I, Hanwell J, Berry C, Aherne W, Hickish T, Martin P and Walker M (1998) Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Canc Chemother Pharmacol 42: 71-76
7. Chabot GG, Abigerges D, Cartimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Herait P, Armand JP and Bugat R (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase 1 trials. Ann Oncol 6: 141-151
8. Clarke SJ, Hanwel J, De Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealy GT and Judson IR (1996) Phase 1 trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumours. J Clin Oncol 14: 1495-1503
9. Cunningham D, Zalcberg JR, Rath U, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D and Perez Manga G (1996) Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7: 961-965
10. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P. A randomised phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients with metastatic colorectal cancer (MCRC) as frontline therapy. Lancet 355:1041-1047
11. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potemsil M (1989) DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048
12. Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG and Allegra CJ (1999) A phase 1 study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Clinical Cancer Research 5: 2381-2391
13. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579-5586
14. Judson I, Maughan TS, Beale P, Primrose J, Hoskin P, Hanwell J, Berry C, Walker M and Sutcliffe F (1998) Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex, ZD1694). Br J Cancer 78(9): 1188-1193
15. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
16. Murad AM, Santiago FF, Petroianu A, Petroianu A, Rocha PRS, Rodrigues MAG and Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin and methotrexale in advaneed gastric cancer. Cancer 72: 37-41
17. Nordic Gastrointestinal Tumor Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colon cancer: a randomized trial. J Clin Oncol 10: 904-911
18. O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW and Potemsil M (1999) Antiangiogenic effects of camptothecin analogs 9-amino-10(S)-camptothecin, topotecan and CPT-11 studied in the mouse cornea model. Clinical Cancer Research 5(1): 181-187
19. Raymond E, Vernillet L, Boige V, Hua A, Ducreux M, Faivre S, Jacques C, Gatineau D, Mignard D, Vergniol JC, Rixe O and Armand JP (1999) Phase I and Pharmacokinetic (PK) Study of Irinotecan (CPT-11) in Cancer Patients (pts) with Hepatic Dysfunction. Proc Am Soc Clin Oncol 18: 165a (abstract 634)
20. Ross PJ, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R and Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001
21. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Many M and Extra JM (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapynaïve patients and patients pretreated with fluorouracil based chemotherapy. J Clin Oncol 15: 251-260
22. Saltz LB, Kanowitz J, Kemeny NE, Schaak L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M and Dietz A (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients wit advanced solid tumors. J Clin Oncol 14: 2959-2967
23. Saltz LB, Locker PK, Pirotta N, Elfring GL and Miller LL (1999) Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (FU) is superior to daily x5 LV/FU in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 18: 233a (abstract 898)
24. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA, Degen D and Von Hoff D (1994) Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5: 202-206
25. Webb A, Cunningham D, Howard Scarffe J, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A and Meehan M (1997) Randomised trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267